Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
87 hedge funds and large institutions have $19.5M invested in Lumos Pharma, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 25 reducing their positions, and 19 closing their positions.
3% more call options, than puts
Call options by funds: $35K | Put options by funds: $34K
5% less funds holding
Funds holding: 92 → 87 (-5)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
28% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 25
43% less capital invested
Capital invested by funds: $34M → $19.5M (-$14.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.42M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$552K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$532K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$251K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.48M |
| 2 |
BlackRock
New York
|
-$753K |
| 3 |
Axa
Paris,
France
|
-$614K |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$593K |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$490K |
LUMO Hedge Fund Activity: Q4 2018 in Review
87 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2018, worth a combined $19.5M — down 43% from $34M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LUMO and 15 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 18 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.42M. The largest seller was Vanguard Group, cutting an estimated $1.48M.
- 87 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2018, down from 92 in Q3 2018.
- Funds reported $19.5M of Lumos Pharma, Inc. Common Stock stock for Q4 2018, down 43% quarter-over-quarter.
- 15 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2018 and 19 closed out, a net change of -4 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2018 was Renaissance Technologies, an estimated $1.42M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q4 2018 was Vanguard Group, an estimated $1.48M sold.
Based on aggregated 13F filings for Q4 2018.